Axogen, Inc.AXGNEarnings & Financial Report
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering (IPO). Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is...
AXGN Q3 2025 Key Financial Metrics
Revenue
$60.1M
Gross Profit
$46.0M
Operating Profit
$1.9M
Net Profit
$708.0K
Gross Margin
76.6%
Operating Margin
3.2%
Net Margin
1.2%
YoY Growth
23.5%
EPS
$0.01
Financial Flow
Axogen, Inc. Q3 2025 Financial Summary
Axogen, Inc. reported revenue of $60.1M for Q3 2025, with a net profit of $708.0K (1.2% margin). Cost of goods sold was $14.1M, operating expenses totaled $44.1M.
Key Financial Metrics
| Total Revenue | $60.1M |
|---|---|
| Net Profit | $708.0K |
| Gross Margin | 76.6% |
| Operating Margin | 3.2% |
| Report Period | Q3 2025 |
Axogen, Inc. Annual Revenue by Year
Axogen, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $187.3M).
| Year | Annual Revenue |
|---|---|
| 2024 | $187.3M |
| 2023 | $159.0M |
| 2022 | $138.6M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $42.9M | $41.4M | $47.9M | $48.6M | $49.4M | $48.6M | $56.7M | $60.1M |
| YoY Growth | 18.7% | 12.9% | 25.6% | 17.9% | 15.1% | 17.4% | 18.3% | 23.5% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $196.8M | $186.5M | $188.9M | $192.0M | $203.7M | $196.2M | $205.5M | $216.4M |
| Liabilities | $101.2M | $93.4M | $93.2M | $92.6M | $99.8M | $90.8M | $93.2M | $95.6M |
| Equity | $95.7M | $93.2M | $95.7M | $99.4M | $103.9M | $105.4M | $112.3M | $120.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-211000 | $-12.3M | $4.2M | $3.9M | $8.7M | $-13.2M | $7.7M | $3.2M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M